The overall sentiment reflects strong agreement that semaglutide effectively reduces appetite and energy intake, supported by posts citing specific studies and mechanisms, whereas the tone and choice of detailed scientific references highlight high interest, engagement, and perceived impact in this field.
AgreementModerate agreement
Most discussions agree that semaglutide reduces appetite, food intake, and cravings, emphasizing its mechanism related to energy intake rather than gastric emptying.
InterestHigh interest
The discussions show high interest, with many posts delving into the drug's mechanisms and clinical findings, indicating active engagement.
EngagementHigh engagement
Posts reference multiple studies and detailed concepts like drug mechanisms and physiological effects, reflecting deep engagement.
ImpactHigh impact
The collective tone suggests that semaglutide's role in obesity treatment is considered highly impactful, potentially reshaping approaches to weight management.
Abstract in brief
The study found that weekly injections of semaglutide 24 mg in obese adults decreased hunger, cravings, and overall food intake, leading to an average weight loss of about 9.9%, compared to almost no change with placebo.
Semaglutide did not significantly affect gastric emptying, meaning it did not slow down how quickly food leaves the stomach, based on measurements of paracetamol absorption.
Participants reported improved control over eating, feeling fuller, and less desire to eat, with a good safety profile consistent with what’s already known about semaglutide.]
Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared to placebo. A few important points:
1⃣ Likely that most of the cardiometabolic benefits are related to CALORIE reduction (supported https://t.co/0gPjRGSRd7 https://t.co/e4iTX3nQmD
Mar 16, 2023 · 64 likes · 10 shares · 16,204 followersView post →
SG
Stephan J. Guyenet
@sguyenet · X
@cremieuxrecueil @ContraNaratives @Babygravy9 It's not the primary mechanism. Delayed gastric emptying with GLP-1 RAs is transient.
https://t.co/OIQoQWsgUB
https://t.co/5Bv4ESDdZO
The primary weight loss mechanism is agonism of brainstem GLP-1 neurons involved in appetite.
https://t.co/P3VdOLKx5p
https://t.co/L8b4jTMqi5
Mar 22, 2024 · 44 likes · 1 share · 53,021 followersView post →
MM
Michael Albert, MD
@MichaelAlbertMD · X
Contrary to popular belief, experimental evidence does NOT support delayed gastric emptying as a meaningful mechanism by which semaglutide affects appetite or weight loss.
[1] https://t.co/68au9YselG
[2] https://t.co/epoCf3SuoT
Jun 19, 2023 · 17 likes · 16,204 followersView post →
MM
Michael Albert, MD
@MichaelAlbertMD · X
In the case of semaglutide 2.4 mg, it promotes a reduction in ad-libitum food consumption via reduced appetite, less preference for energy dense fatty foods, and reduced cravings. https://t.co/WLx3nPwwXi
Semaglutide – a once weekly human glp-1 analogue has been shown to reduce hunger, increase satiety and reduced food cravings (Friedrichsen et al) https://t.co/WeRiMZNbhu https://t.co/wsS83FXQ4N
This video discusses the impact of weekly semaglutide 2.4 mg injections on appetite, cravings, and weight loss in obese adults. The study shows significant decreases in hunger and food intake, with an average weight…
GLP-1 and dual GLP1GIP medications are transforming obesity treatment. This session explains how these drugs support weight loss, their costs, utilization trends, and compares them with lifestyle approaches…
GLP-1 and dual GLP-1/GIP medications are reshaping obesity treatment, but what do Regulators and Consumers need to know about these popular treatments? Watch our recent webinar to learn about the effectiveness and impact of these drugs. https://t.co/Vtb0jjLXvX
@MichaelMindrum We have some data:
Lower preference for high-fat foods
Fewer cravings
Better control of eating
Decreased appetite
[1] https://t.co/X1f1lKZXBl
[2] https://t.co/0gPjRGSjnz
Mar 30, 2024 · 1 like · 16,204 followersView post →
T
Tyler
@tyzzly · X
RT @sguyenet: @cremieuxrecueil @ContraNaratives @Babygravy9 It's not the primary mechanism. Delayed gastric emptying with GLP-1 RAs is tra…
@cremieuxrecueil @ContraNaratives @Babygravy9 It's not the primary mechanism. Delayed gastric emptying with GLP-1 RAs is transient.
https://t.co/OIQoQWsgUB
https://t.co/5Bv4ESDdZO
The primary weight loss mechanism is agonism of brainstem GLP-1 neurons involved in appetite.
https://t.co/P3VdOLKx5p
https://t.co/L8b4jTMqi5
Mar 22, 2024 · 44 likes · 1 share · 53,021 followersView post →
MM
Michael Weintraub, MD
@MWeintraubMD · X
However, another study showed semaglutide 2.4mg had no effect on delaying gastric emptying at 20 weeks, suggesting a possible tachyphylaxis
https://t.co/EjXd6CSHVp
Aug 15, 2023 · 3 likes · 4,802 followersView post →
MM
Michael Albert, MD
@MichaelAlbertMD · X
Contrary to popular belief, experimental evidence does NOT support delayed gastric emptying as a meaningful mechanism by which semaglutide affects appetite or weight loss.
[1] https://t.co/68au9YselG
[2] https://t.co/epoCf3SuoT
Jun 19, 2023 · 17 likes · 16,204 followersView post →
SW
Stephen Winters
@stephen_winters · X
RT @MichaelAlbertMD: Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared…
Mar 17, 2023 · 10 shares · 534 followersView post →
JC
Joe Zucchi, PA-C, CPT
@JPZfitness · X
RT @MichaelAlbertMD: Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared…
Mar 17, 2023 · 10 shares · 248 followersView post →
RR
Rafael Radaeli
@rfradaeli · X
RT @MichaelAlbertMD: Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared…
Mar 16, 2023 · 10 shares · 384 followersView post →
GA
Getting Active
@ActiveGetting · X
RT @MichaelAlbertMD: Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared…
Mar 16, 2023 · 10 shares · 22 followersView post →
MM
Michael Cudworth, MD, FACS, DABS-FPD MBS
@mcudworth_MD · X
RT @MichaelAlbertMD: Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared…
Mar 16, 2023 · 10 shares · 1,201 followersView post →
G
GDLeahy
@GDLeahy · X
RT @MichaelAlbertMD: Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared…
Mar 16, 2023 · 10 shares · 673 followersView post →
JM
Jossy Onwude, MD
@DrOnwude · X
RT @MichaelAlbertMD: Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared…
Mar 16, 2023 · 10 shares · 1,763 followersView post →
TP
Tony Piassa
@TonyPiassa · X
RT @MichaelAlbertMD: Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared…
Mar 16, 2023 · 10 shares · 199 followersView post →
BJ
Bayar Jaff
@JaffBayar · X
RT @MichaelAlbertMD: Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared…
Mar 16, 2023 · 10 shares · 607 followersView post →
AM
Austin Baraki, MD
@AustinBaraki · X
RT @MichaelAlbertMD: Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared…
Mar 16, 2023 · 10 shares · 4,884 followersView post →
MM
Michael Albert, MD
@MichaelAlbertMD · X
Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared to placebo. A few important points:
1⃣ Likely that most of the cardiometabolic benefits are related to CALORIE reduction (supported https://t.co/0gPjRGSRd7 https://t.co/e4iTX3nQmD
Mar 16, 2023 · 64 likes · 10 shares · 16,204 followersView post →
MM
Michael Albert, MD
@MichaelAlbertMD · X
Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared to placebo. A few important points:
1⃣ Likely that most of the cardiometabolic benefits are related to CALORIE reduction (supported https://t.co/0gPjRGSRd7 https://t.co/PX5AzOjTCi
Mar 16, 2023 · 1 like · 16,204 followersView post →
MM
Michael Albert, MD
@MichaelAlbertMD · X
Semaglutide reduces ad libitum energy intake by 35% (through its effects on appetite, reward, and food drive) compared to placebo. A few important points:
1⃣ Likely that most of the cardiometabolic benefits are related to CALORIE reduction (verified by https://t.co/0gPjRGSRd7 https://t.co/Ifol4kefhr
@JimmySteier @SCHIZO_FREQ As I'm checking in to this, looks like it doesn't even delay gastric emptying when used for obesity. Mechanism of action is probably something else. https://t.co/srXH2oKTAf
In the case of semaglutide 2.4 mg, it promotes a reduction in ad-libitum food consumption via reduced appetite, less preference for energy dense fatty foods, and reduced cravings. https://t.co/WLx3nPwwXi
@ethanjweiss @DanielJDrucker @NEJM #GLP and weight loss MoA is fairly well described. In patients showing strong energy intake reduction https://t.co/Vfpve35q7p. Additional details on access to and effects in the brain using animal models here https://t.co/nefOEsaoiQ.
Study finds that obesity drug semaglutide supresses appetite, food cravings and energy intake
https://t.co/ijNviKQbnt
https://t.co/yCJgjpFO7F https://t.co/n9SlmIlGOy
Semaglutide – a once weekly human glp-1 analogue has been shown to reduce hunger, increase satiety and reduced food cravings (Friedrichsen et al) https://t.co/WeRiMZNbhu https://t.co/wsS83FXQ4N
Trials looking specifically at semaglutide vs placebo on appetite and energy intake:
1. Blundell 2017 (1 mg/wk) - reduced ad lib kcal intake, lower hunger & food cravings. https://t.co/Krrx268mWS
2. Friedrichsen 2020 (2.4 mg/wk) - similar outcomes https://t.co/3K7vsCWxcp
Feb 11, 2021 · 4 likes · 9,206 followersView post →
UV
Uku Vainik
@ukuv · X
RT @DavidMacklinMD: @KevinH_PhD @seeleyrj @michael_krashes Note the never before seen COEQ data suggesting significant inhibition of incent…
Feb 11, 2021 · 1 share · 1,129 followersView post →
DM
David Macklin
@DavidMacklinMD · X
@KevinH_PhD @seeleyrj @michael_krashes Note the never before seen COEQ data suggesting significant inhibition of incentive motivation/wanting/craving in those treated with Semaglutide 2.4mg. Very consistent with my clinical patient experience. https://t.co/vnhrPcyvKB
Feb 10, 2021 · 2 likes · 1 share · 1,887 followersView post →
RR
Rafael Radaeli
@rfradaeli · X
RT @DanielJDrucker: Pharmacodynamic profiles (gastric emptying, food intake, hunger) of 20 weeks of semaglutide 2.4 mg once weekly in peopl…
RT @DanielJDrucker: Pharmacodynamic profiles (gastric emptying, food intake, hunger) of 20 weeks of semaglutide 2.4 mg once weekly in peopl…
Dec 4, 2020 · 3 shares · 1,178 followersView post →
DD
Daniel J Drucker
@DanielJDrucker · X
Pharmacodynamic profiles (gastric emptying, food intake, hunger) of 20 weeks of semaglutide 2.4 mg once weekly in people with #obesity https://t.co/nuiUuKfRLq
Dec 4, 2020 · 4 likes · 3 shares · 35,002 followersView post →
N
BJP 2024 3F | PDF
News
Izdatilskii dom Piter.] Ериксън, Е. (1996). Идентичност, младост и криза ... The Economic Journal, 113(489), 614–630. doi:https://doi.org/10.1111/1468-0297.t01-1- ...
... 14280 ± 120 BP). Na rozdíl od gravettienu (pavlovienu) jsou re- tušované ... dom- feature), long bones (ulna? and a humerus in pit 1, a tibia in DJ 1) ...
Fungal Associations, Third Edition (Springer, 2024) | PDF | Fungus ...
News
372 dom levels. In: Anke T, Weber D (eds) Physiology and. Jeandroz S, Murat C ... 10.1111/j.1469-8137.1986. Dal Grande F, Sharma R, Meiser A, Rolshausen ...
14280 21. McEvoy BW. Missing data in clinical trials for liraglutide in ... doi:10.1111/dom.13804 drugs-and-biological-products 2 diabetes (DiRECT): an ...
Practice: Endocrine | PDF | Obesity | Body Mass Index
News
https://doi.org/10.4158/ep14280.Ps. in complication-centric care based ... https://doi.org/10.1111/dom.15272. 10.3949/ccjm.91a.24068. 258. de Lemos JA ...
Tirzepatide vs Semaglutide for Obesity | PDF | Clinical Medicine ...
News
doi:10.1111/dom.14280 19. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, 28. Jensterle M, Ferjan S, Ležaič L, et al. Semaglutide delays 4-hour gas-
How are you keeping other medications effective? : r/Retatrutide
Reddit
... medication absorption vs the control after 20 weeks. https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14280 · Dustin_marie. OP ...
MM
SG
CM
T
MM
SW
JC
RR
GA
MM
G
JM
TP
BJ
AM
AC
MH
AS
LK
AB
CM
KF
TR
UV
DM
ME
DD